Multiple Sclerosis (MS) KOL Interview – UK, London

Multiple Sclerosis (MS) KOL Interview – UK, London

  • March 2020 •
  • 14 pages •
  • Report ID: 5878949 •
  • Format: PDF
In this interview, a UK-based key opinion leader (KOL) discusses typical prescribing habits for disease-modifying therapies (DMTs) in MS. This includes first-generation DMTs and the newer, more potent entrants like Ocrevus, as well as late-stage pipeline DMTs.